Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Yervoy

- PMLiVE

Bristol Myers Squibb’s Augtyro granted expanded FDA approval for solid tumours

The drug was approved by the US regulator last year to treat ROS1-positive NSCLC

- PMLiVE

BMS shares positive phase 3 results for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for 90% of all liver cancer cases and is often diagnosed at an advanced stage

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

Bristol Myers Squibb’s Opdivo approved by EC for adults with urothelial carcinoma

UC accounts for approximately 90% of all bladder cancers, the ninth most common cancer globally

- PMLiVE

Bristol Myers Squibb unveils ten-year strategy to improve access to medicines in LMICs

The company has collaborated with the ATOM Coalition to make Opdivo available in select countries

- PMLiVE

Bristol Myers Squibb’s Breyanzi granted FDA accelerated approval for follicular lymphoma

The disease accounts for up to 30% of all non-Hodgkin lymphoma cases

- PMLiVE

Bristol Myers Squibb and Repertoire enter autoimmune disease partnership worth over $1.8bn

It is estimated that up to 50 million people in the US have an autoimmune disease

- PMLiVE

BMS and Shine Cancer Support’s UK research reveals disparities in cancer diagnosis

The Cancer Equals campaign and 1,000 Voices, Not 1 report aim to help address reasons for diagnostic delays

- PMLiVE

BMS and 2seventy’s multiple myeloma therapy Abecma receives expanded FDA approval

More than 35,700 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Bristol Myers Squibb’s Reblozyl receives EC approval in myelodysplastic syndromes

The treatment is already approved in the EU to treat anaemia in adults with beta-thalassaemia

- PMLiVE

Bristol Myers Squibb shares positive phase 3 results for Krazati in non-small cell lung cancer

KRAS G12C occurs in approximately 14% of NSCLC, the most common form of lung cancer

- PMLiVE

Bristol Myers Squibb shares positive results for Opdivo combination in advanced liver cancer

HCC is the most common primary liver cancer, accounting for 90% of all cases of liver cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links